Finance

Lists
500124:BOM
Dr Reddy's Laboratories Ltd
1 231,85 INR
+0,91%
(+11,10) 1D
16-окт., 15:59:49 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500124...
Open
1 227,10 INR
High
1 231,85 INR
Low
1 213,80 INR
Mkt. cap
1,02 трлн
Avg. vol.
87,44 миң
Volume
77,54 миң
Dividend
0,65%
Quarterly dividend
2,00 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,85
52-wk high
1 414,40 INR
52-wk low
1 080,05 INR
EPS
38,67 INR
Shares outstanding
166,06 млн
No. of employees
28 миң
Open
1 227,10 INR
High
1 231,85 INR
Low
1 213,80 INR
Mkt. cap
1,02 трлн
Avg. vol.
87,44 миң
Volume
77,54 миң
Dividend
0,65%
Quarterly dividend
2,00 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,85
52-wk high
1 414,40 INR
52-wk low
1 080,05 INR
EPS
38,67 INR
Shares outstanding
166,06 млн
No. of employees
28 миң
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 миң
Founded1984
HeadquartersHyderabad, Эндра Прадеш, Индия
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
88,05 млд
87,27 млд
75,16 млд
80,70 млд
Cost of goods sold
39,91 млд
40,46 млд
41,47 млд
43,16 млд
Cost of revenue
39,91 млд
40,46 млд
41,47 млд
43,16 млд
Research and development expenses
6,20 млд
6,15 млд
5,46 млд
5,77 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 млд
26,92 млд
27,76 млд
28,82 млд
Operating expense
31,90 млд
32,48 млд
32,53 млд
34,11 млд
Total operating expenses
71,81 млд
72,94 млд
74,00 млд
77,27 млд
Operating income
16,24 млд
14,33 млд
1,16 млд
3,43 млд
Other non operating income
1,28 млд
570,00 млн
512,00 млн
-
EBT including unusual items
18,35 млд
15,43 млд
1,99 млд
5,53 млд
EBT excluding unusual items
17,81 млд
15,52 млд
1,82 млд
4,09 млд
Income tax expense
4,08 млд
3,53 млд
-214,00 млн
1,18 млд
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 млн
-591,00 млн
-693,00 млн
-477,00 млн
Net income
14,37 млд
12,10 млд
2,20 млд
4,44 млд
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 млн
796,00 млн
890,00 млн
999,00 млн
Interest expense
-907,00 млн
-944,00 млн
-1,06 млд
-1,26 млд
Net interest expenses
5,00 млн
-148,00 млн
-167,00 млн
-256,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 млд
19,54 млд
5,03 млд
8,80 млд
Gain or loss from assets sale
-308,00 млн
-179,00 млн
-2,10 млд
-368,00 млн
AI content may include mistakes. Learn more
Google колдонмолору